Skip to main content

Table 2 Odds ratio for disease development of anti-CCP2 antibodies and different ACPA prior to symptoms of RA (pre-RA), ≤10.5 years prior to symptoms, and at diagnosis in combination with HLA-SE allele (none/any), smoking (never/ever)

From: Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis

  

Pre-RA (ever-pos)

Pre-RA (≤10.5 years)

RA

(n = 348)

(n = 277)

(n = 196)

HLA-SE

Smoking

OR (95% CI)

OR (95% CI)

OR (95% CI)

Anti-CCP2

    

None

Never

1.00 (Ref)

1.00 (Ref)

1.00 (Ref)

Any

Never

1.36 (0.57–3.22)

1.81 (0.81–4.00)

1.06 (0.36–3.14)

None

Ever

1.50 (0.64–3.53)

1.41 (0.62–3.22)

1.02 (0.36–2.88)

Any

Ever

2.36 (1.08–5.17)

3.96 (1.87–8.39)

4.23 (1.42–12.59)

Anti-CEP-1/Eno5-21

   

None

Never

1.00 (Ref)

1.00 (Ref)

1.00 (Ref)

Any

Never

1.40 (0.56–3.55)

1.08 (0.46–2.55)

1.44 (0.51–4.03)

None

Ever

1.38 (0.55–3.48)

1.38 (0.59–3.27)

1.92 (0.70–5.26)

Any

Ever

2.25 (0.97–5.23)

2.85 (1.30–6.24)

6.59 (2.42–17.99)

Anti-CitC1359-369

    

None

Never

1.00 (Ref)

1.00 (Ref)

1.00 (Ref)

Any

Never

1.20 (0.29–4.92)

1.74 (0.47–6.54)

3.88 (0.44–34.48)

None

Ever

2.00 (0.52–7.64)

2.28 (0.61–8.47)

14.93 (1.85–120.33)

Any

Ever

2.59 (0.74–9.07)

4.05 (1.19–13.82)

14.67 (1.89–113.98)

Anti-Fibα580-600 (591)

None

Never

1.00 (Ref)

1.00 (Ref)

1.00 (Ref)

Any

Never

1.31 (0.38–4.47)

1.57 (0.41–5.96)

0.17 (0.02–1.75)

None

Ever

0.61 (0.15–2.40)

0.88 (0.20–3.83)

1.37 (0.33–5.73)

Any

Ever

0.69 (0.20–2.26)

1.39 (0.38–5.07)

1.32 (0.34–5.03)

Anti-Fibα563-583 (573)

None

Never

1.00 (Ref)

1.00 (Ref)

1.00 (Ref)

Any

Never

1.61 (0.31–8.34)

1.89 (0.39–9.21)

2.22 (0.54–9.09)

None

Ever

2.79 (0.58–13.42)

3.16 (0.67–14.84)

3.13 (0.80–12.17)

Any

Ever

3.09 (0.69–13.79)

3.42 (0.77–15.17)

5.14 (1.42–18.61)

Anti-Fibβ62-81a (72)

None

Never

1.00 (Ref)

1.00 (Ref)

1.00 (Ref)

Any

Never

4.98 (1.09–22.90)

4.90 (0.61–39.36)

2.44 (0.26–23.30)

None

Ever

1.58 (0.31–8.23)

3.33 (0.39–28.40)

1.50 (0.15–15.27)

Any

Ever

2.76 (0.61–12.36)

6.99 (0.91–53.38)

5.91 (0.75–46.86)

Anti-Fibβ62-81b (74)

    

None

Never

1.00 (Ref)

1.00 (Ref)

1.00 (Ref)

Any

Never

2.00 (0.52–7.64)

7.14 (0.91–55.83)

2.53 (0.63–10.23)

None

Ever

2.00 (0.52–7.64)

6.45 (0.81–51.41)

2.55 (0.65–10.05)

Any

Ever

3.52 (1.02–12.20)

16.73 (2.24–124.88)

5.93 (1.64–21.44)

Anti-Fibβ36-52

    

None

Never

1.00 (Ref)

1.00 (Ref)

1.00 (Ref)

Any

Never

1.20 (0.50–2.86)

1.45 (0.58–3.67)

0.85 (0.30–2.39)

None

Ever

1.18 (0.49–2.81)

1.65 (0.65–4.20)

0.80 (0.29–2.19)

Any

Ever

1.64 (0.74–3.61)

3.64 (1.54–8.57)

3.08 (1.15–8.21)

Anti-CCP-1/Fil307-324

    

None

Never

1.00 (Ref)

1.00 (Ref)

1.00 (Ref)

Any

Never

1.81 (0.73–4.51)

3.67 (1.34–10.06)

0.66 (0.23–1.85)

None

Ever

1.20 (0.47–3.06)

1.97 (0.68–5.69)

0.51 (0.18–1.42)

Any

Ever

1.77 (0.76–4–14)

4.05 (1.52–10.79)

1.42 (0.56–3.56)

Anti-Vim60−75

    

None

Never

1.00 (Ref)

1.00 (Ref)

1.00 (Ref)

Any

Never

1.42 (0.47–4.32)

6.56 (0.84–51.59)

2.53 (0.63–10.23)

None

Ever

0.58 (0.17–2.04)

2.74 (0.31–24.11)

1.17 (0.27–5.00)

Any

Ever

1.02 (0.35–2.91)

6.20 (0.81–47.64)

4.67 (1.29–16.92)

Anti-Vim2-17

    

None

Never

1.00 (Ref)

1.00 (Ref)

1.00 (Ref)

Any

Never

1.04 (0.09–11.83)

2.34 (0.27–20.54)

1.41 (0.33–6.10)

None

Ever

2.67 (0.30–23.68)

2.17 (0.24–19.94)

0.62 (0.13–3.04)

Any

Ever

4.99 (0.64–38.65)

6.20 (0.81–47.64)

0.69 (0.17–2.85)

  1. Significant associations presented in bold. HLA-SE= HLA shared epitope, OR= odds ratio, CI= confidence intervals, anti-CCP2=anti-cyclic citrullinated peptide antibodies, anti CEP-1/Eno5-21= antibodies against α-Enolase, anti-citC1359-369= antibodies against collagen type II aa 359-369 with two citrulline residues, anti- Fibα580-600=antibodies against fibrinogen (Fib) Fibα580-600, anti-Fibα561-583= antibodies against Fibα561-583, anti- Fibβ62-81a(72)=antibodies against Fibβ62-81a(72), anti-Fibβ62-81b(74)= antibodies against Fibβ62-81b(74), anti-Fibβ36-52= antibodies against Fibβ36-52, anti- CCP-1/Fil307-324= antibodies against filaggrin, anti- Vim60-75= antibodies against vimentin (Vim)60-75, anti-Vim2-17= antibodies against Vim 2-17.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us